Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Lipton

Showing results (21-30 of 148) with videos related to

Pageof 15
Sort By:
Cancer|January 28, 2003
Bisphosphonates and metastatic breast carcinomaAllan Lipton
Expert Opinion on Drug Safety|May 8, 2007
The safety of zoledronic acidAllan Lipton
Current Opinion in Supportive and Palliative Care|August 13, 2010
New approaches to treating and preventing bone metastasesAllan Lipton
Current Opinion in Supportive and Palliative Care|August 8, 2008
RANKL inhibition in the treatment of bone metastasesAllan Lipton, Susie Jun
BJU International|May 12, 2006
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancersFred Saad, Allan Lipton
BJU International|October 18, 2005
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancersFred Saad, Allan Lipton
Bone|October 19, 2010
Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasisAllan Lipton, Carsten Goessl
Expert Review of Clinical Pharmacology|September 5, 2012
Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumorsAllan Lipton, Arun Balakumaran
Cancer Investigation|October 1, 2010
Anticancer properties of zoledronic acidJonathan Green, Allan Lipton
Seminars in Oncology|November 30, 2010
Antitumor effects and anticancer applications of bisphosphonatesGareth Morgan, Allan Lipton
Pageof 15

Showing results (21-30 of 148) with videos related to

Sort By:
Pageof 15
Cancer|January 28, 2003
Bisphosphonates and metastatic breast carcinomaAllan Lipton
Expert Opinion on Drug Safety|May 8, 2007
The safety of zoledronic acidAllan Lipton
Current Opinion in Supportive and Palliative Care|August 13, 2010
New approaches to treating and preventing bone metastasesAllan Lipton
Current Opinion in Supportive and Palliative Care|August 8, 2008
RANKL inhibition in the treatment of bone metastasesAllan Lipton, Susie Jun
BJU International|May 12, 2006
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancersFred Saad, Allan Lipton
BJU International|October 18, 2005
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancersFred Saad, Allan Lipton
Bone|October 19, 2010
Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasisAllan Lipton, Carsten Goessl
Expert Review of Clinical Pharmacology|September 5, 2012
Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumorsAllan Lipton, Arun Balakumaran
Cancer Investigation|October 1, 2010
Anticancer properties of zoledronic acidJonathan Green, Allan Lipton
Seminars in Oncology|November 30, 2010
Antitumor effects and anticancer applications of bisphosphonatesGareth Morgan, Allan Lipton
Pageof 15